OncoConnect Journal Club: Treating lenalidomide exposed patients in RRMM
Prescribing information is available at the top of the page.
Listen to Dr Andrew Charlton discuss the importance of considering re-treatment of multiple myeloma patients with lenalidomide-based therapies beyond the front-line setting , where they may have been exposed to but not refractory to lenalidomide. Andrew Charlton also discusses the background and some supporting evidence for the two commonly used front-line lenalidomide-based regimens in the UK: front-line therapy in non-transplant eligible patients, in combination with dexamethasone and in a maintenance role in post-ASCT patients. The impact of lenalidomide re-challenge in patients previously exposed to lenalidomide was also reviewed during this presentation.
NINLARO® (ixazomib) in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Sign up to stay in touch and receive information on upcoming journal clubs.
AEs, adverse events; Post- ASCT, post autologous stem cell transplant; RRMM, relapsed refractory multiple myeloma; UK, United Kingdom.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
